文献速递胸部肿瘤

同步放化疗与I-II期及III期小细胞肺癌患者结局的相关性:一项随机临床试验的二次分析

Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-03-14

该研究为CONVERT试验的事后二次分析,纳入509例有TNM分期信息的局限期小细胞肺癌患者,其中86例(16.9%)为I-II期。I-II期患者接受同步放化疗后中位总生存期50个月,显著长于III期患者的25个月(HR 0.60,95%CI 0.44-0.83,P=.001);I-II期患者中每日一次与每日两次放疗组生存无显著差异。

要点

  • I-II期小细胞肺癌患者接受同步放化疗后中位总生存期为50个月,III期患者为25个月(HR 0.60)。
  • I-II期患者中每日一次与每日两次放疗组的中位生存期分别为39个月和72个月,无显著差异(P=.38)。
  • I-II期患者≥3级急性食管炎发生率为11.3%,低于III期患者的21.1%(P<.001)。

核心结论

  • CONVERT试验中I-II期小细胞肺癌患者接受同步放化疗及预防性颅脑照射后获得长期生存且毒性可接受。
  • 该研究提示接受现代同步放化疗的I-II期小细胞肺癌患者结局优于III期患者,可为临床决策提供参考信息。

研究设计与样本

  • CONVERT试验是一项多中心3期随机对照试验,于2008年4月7日至2013年11月29日纳入局限期小细胞肺癌患者。
  • 本分析为CONVERT试验的事后二次分析,比较TNM I-II期与III期小细胞肺癌患者,数据分析了2017年11月1日至2018年2月28日进行。
  • CONVERT试验中患者随机接受每日两次放疗(45 Gy/30次)或每日一次放疗(66 Gy/33次)的同步放化疗,并按指征给予预防性颅脑照射。
  • 543例患者中509例(93.7%)有TNM分期信息并纳入本亚组分析,其中86例(16.9%)为I-II期;277例(54.4%)为男性,平均(SD)年龄61.5(8.3)岁。
  • 本分析为未计划的分析,因试验未按TNM分期进行分层。

主要发现

  • I-II期患者的中位肿瘤大体体积为38.4 cm³(范围2.2-593.0 cm³),小于III期患者的93 cm³(范围0.5-513.4 cm³)(P<.001)。
  • 两组基线特征、治疗特征及同步放化疗依从性无其他显著差异;I-II期患者中78例(90.7%)接受预防性颅脑照射,III期患者中346例(81.8%)接受(P=.10)。
  • I-II期患者的中位总生存期为50个月(95%CI 38个月至未达到),III期患者为25个月(95%CI 21-29个月),风险比为0.60(95%CI 0.44-0.83),P=.001。
  • 在I-II期患者中,每日一次放疗组与每日两次放疗组的中位生存期分别为39个月和72个月,无显著生存差异(P=.38)。
  • I-II期患者≥3级急性食管炎发生率为11.3%(9例),低于III期患者的21.1%(82例)(P<.001);急性和晚期毒性反应发生率无其他显著差异。

局限性

  • 本分析为未计划的分析,因试验未按TNM分期进行分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is limited evidence to guide stage I to II small cell lung cancer (SCLC) treatment. OBJECTIVE: To examine the characteristics and outcomes among patients with stage I to II SCLC treated with modern chemoradiotherapy. DESIGN, SETTING, AND PARTICIPANTS: In this post hoc secondary analysis of the Concurrent Once-Daily vs Twice-Daily Radiotherapy Trial (CONVERT), a multicenter phase 3 trial conducted in patients with limited-stage SCLC from April 7, 2008, to November 29, 2013, patients with TNM stage I to II SCLC were compared with those with stage III disease. Data analysis was performed from November 1, 2017, to February 28, 2018. INTERVENTIONS: In CONVERT, patients were randomized to receive twice-daily (45 Gy in 30 fractions) or once-daily (66 Gy in 33 fractions) chemoradiotherapy. Prophylactic cranial irradiation (PCI) was offered, if indicated. MAIN OUTCOMES AND MEASURES: The primary trial end point was overall survival (OS). TNM staging information was collected prospectively; this was an unplanned analysis because stratification was not performed according to TNM stage. RESULTS: A total of 509 (277 [54.4%] men; mean [SD] age, 61.5 [8.3] years) of 543 patients (93.7%) with TNM staging information were eligible for this subgroup analysis, and 86 of the 509 (16.9%) had TNM stage I to II disease. The median gross tumor volume was smaller in patients with stage I to II disease (38.4 cm3; range, 2.2-593.0 cm3) compared with patients with stage III disease (93 cm3; range, 0.5-513.4 cm3) (P < .001). No other significant differences were found in baseline and treatment characteristics and chemoradiotherapy adherence between the 2 groups or the number of patients with stage I to II disease (78 [90.7%]) and stage III disease (346 [81.8%]) who received PCI (P = .10). Patients with stage I to II disease achieved longer OS (median, 50 months [95% CI, 38 to not reached months] vs 25 months [95% CI, 21-29 months]; hazard ratio, 0.60 [95% CI, 0.44-0.83]; P = .001) compared with patients with stage III disease. In patients with stage I to II disease, no significant survival difference was found between the trial arms (median, 39 months in the once-daily arm vs 72 months in the twice-daily arm; P = .38). Apart from lower incidence of acute esophagitis in patients with stage I to II disease compared with patients with stage III disease (grade ≥3, 9 [11.3%] vs 82 [21.1%]; P < .001), the incidences of acute and late toxic effects were not significantly different. CONCLUSIONS AND RELEVANCE: Patients with stage I to II SCLC in CONVERT achieved long-term survival with acceptable toxic effects after chemoradiotherapy and PCI. This study suggests that patients with stage I to II small cell lung cancer treated with modern chemoradiotherapy have better outcomes compared with patients with stage III disease, providing information that practitioners can potentially give their patients to aid clinical decisions. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00433563.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Salem A, Mistry H, Hatton M, et al. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30520977. doi:10.1001/jamaoncol.2018.5335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。